San Mateo, California-based RevaGenix has received a USD 12.1 million National Institute of Allergy and Infectious Diseases (NIAID) contract to advance therapeutics targeting antimicrobial-resistant infections, biodefense pathogens, and emerging infectious diseases through early clinical development.
The contract, administered by the National Institute of Allergy and Infectious Diseases (NIAID) and running through September 2026, supports a multi-stage development program spanning lead optimization, candidate selection, investigational new drug (IND)-enabling studies, chemistry, manufacturing and controls (CMC) work, IND submission, and early clinical safety and efficacy assessment. The breadth of activities funded under a single contract reflects NIAID's continued use of R&D contract vehicles to accelerate translational progression in areas where commercial investment alone has proven insufficient — a pattern seen across multiple AMR programs in recent years.
P. aeruginosa is a priority pathogen for global health agencies, including the World Health Organization, which has listed carbapenem-resistant strains among its critical-priority organisms. The bacterium's intrinsic resistance mechanisms and capacity to acquire additional resistance determinants have narrowed available treatment options, sustaining demand for novel therapeutic approaches. The contract identifies Pseudomonas aeruginosa as one of the target pathogens but does not disclose the therapeutic modality or specific development candidates.
Principal investigator Ryan T. Cirz leads the program at RevaGenix. The award is structured as a domestic for-profit R&D contract, consistent with NIAID's strategy of engaging biotechnology companies directly in late-preclinical and early-clinical AMR development where academic settings are less suited to regulatory-track product advancement.